Deep Dives into Peptide Science
Research breakdowns, protocol design, and the latest findings from the world of peptide science. Written for researchers who care about the evidence.
CagriSema Beat High-Dose Semaglutide on HbA1c. The Margin Was Smaller Than the Headline
A 2,713-person phase 3 trial found CagriSema lowered HbA1c more than semaglutide 2.4 mg. The win was significant, but the average margin was 0.16 percentage points.
A Peptide Vaccine Made Humans Produce Antibodies Against IL-17A. That Is the Start, Not the Finish.
A 20-person Phase 1 trial found that FPP003 induced anti-IL-17A antibodies without severe or serious adverse events. Here is what that proves, and what it does not.
Can GLP-1 Drugs Slow Parkinson’s? The New Meta-Analysis Hides a Split Verdict
A positive 2026 meta-analysis clashes with a negative phase 3 trial and other reviews. Here is why the same GLP-1 evidence produces opposite Parkinson’s headlines.
DD01 Cut Liver Fat in 12 Weeks. Here's What the Phase 2 Trial Really Proved
In a randomized phase 2 trial, 76% of DD01 participants cut liver fat by at least 30% in 12 weeks. The efficacy signal was strong, but nausea and vomiting were common.
A Longer-Lasting Thymosin Beta-4 Repaired Heart-Attack Damage in Rats. Human Proof Is the Hard Part.
A new PEGylated thymosin beta-4 lasted four times longer and improved heart function after myocardial infarction in rats. The formulation is promising, but the human evidence is still mixed.
A Phase 3 Peptide Stroke Trial Failed. The Severe-Stroke Signal Is Hard to Ignore
A new phase 3 trial found no overall benefit from EGF plus GHRP-6 after ischemic stroke, but a small severe-stroke subgroup showed lower disability and mortality.
GLP-1 Drugs, Anxiety, and Depression: What the New Data Actually Says
A large real-world study just compared semaglutide and tirzepatide to older weight-loss drugs on mental health outcomes. The results split in an unexpected direction.
Amylin Therapies: The Next Generation of Weight-Loss Drugs Beyond GLP-1s
New clinical data from ADA 2026 and ECO 2026 shows amylin-based therapies delivering double-digit weight loss with better muscle preservation and fewer GI side effects than GLP-1s alone. Here's why every major pharma company is building an amylin program.
Survodutide Cuts Liver Fat by 63% and Visceral Fat by 34% — Why the Weight Loss Numbers Tell Only Half the Story
The SYNCHRONIZE-1 trial showed survodutide delivers 16.6% weight loss, but the real story is what happens to the fat you can't see — deep visceral and liver fat that drives cardiometabolic disease.
VK2735: The Oral Weight Loss Pill That Lost 26 Pounds in 13 Weeks
Viking Therapeutics just showed that their oral dual GLP-1/GIP agonist VK2735 produced 12.2% weight loss in 13 weeks — no injections required. Here's what the Phase 2 data means for the future of weight loss pills.
Survodutide Shrinks Liver Fat by 84% in Phase 3 Trial — A New Era for Fatty Liver Disease
A landmark Nature Medicine trial shows survodutide dramatically reduces liver fat and body weight in patients with fatty liver disease. Here's what the data actually says.